Literature DB >> 3840584

Two-site "simultaneous" immunoassay with monoclonal antibodies for the determination of surfactant apoproteins in human amniotic fluid.

Y Kuroki, H Takahashi, Y Fukada, M Mikawa, A Inagawa, S Fujimoto, T Akino.   

Abstract

Monoclonal antibodies against human surfactant apoproteins were prepared, which recognized 37, 34, and 62 kilodalton proteins in human lung lavage fluid and amniotic fluid. Two-site "simultaneous" immunoassay for the surfactant apoproteins was developed using the monoclonal antibodies. The assay was capable of measuring 10-640 ng of the apoproteins per ml of human amniotic fluid. The immunoassay was used to quantitate the apoproteins in 59 amniotic fluid samples from 23 to 41 wk gestation. The concentration of the surfactant apoproteins at less than 30 wk gestation was very low (mean 0.84 micrograms/ml). It then increased 6.5-fold from 34 to 36 wk gestation and 15.5-fold at more than 37 wk gestation. The simultaneous immunoassay with the monoclonal antibodies presented herein seems to be ideal for clinical use because of its high specificity, sensitivity, rapidity, simplicity, and a continuous unlimited supply of the antibodies. The results in this study show that the clinical use of the two-site simultaneous immunoassay with monoclonal antibodies to pulmonary surfactant apoproteins can predict fetal lung maturity more precisely.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3840584     DOI: 10.1203/00006450-198510000-00013

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  9 in total

Review 1.  Function and regulation of expression of pulmonary surfactant-associated proteins.

Authors:  T E Weaver; J A Whitsett
Journal:  Biochem J       Date:  1991-01-15       Impact factor: 3.857

2.  Surfactant abnormalities in infants with severe viral bronchiolitis.

Authors:  P A Dargaville; M South; P N McDougall
Journal:  Arch Dis Child       Date:  1996-08       Impact factor: 3.791

3.  Detection of the type II cell or its precursor before week 20 of human gestation, using antibodies against surfactant-associated proteins.

Authors:  C J Otto-Verberne; A A Ten Have-Opbroek; J J Balkema; C Franken
Journal:  Anat Embryol (Berl)       Date:  1988

4.  Immunohistochemical study of human pulmonary surfactant apoproteins with monoclonal antibodies. Pathologic application for hyaline membrane disease.

Authors:  Y Kuroki; K Dempo; T Akino
Journal:  Am J Pathol       Date:  1986-07       Impact factor: 4.307

5.  Stable microbubble test for predicting the risk of respiratory distress syndrome: I. Comparisons with other predictors of fetal lung maturity in amniotic fluid.

Authors:  S Chida; T Fujiwara
Journal:  Eur J Pediatr       Date:  1993-02       Impact factor: 3.183

6.  Regulation of pulmonary surfactant apoprotein SP 28-36 gene in fetal human lung.

Authors:  P L Ballard; S Hawgood; H Liley; G Wellenstein; L W Gonzales; B Benson; B Cordell; R T White
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

7.  Expression of the 35kDa and low molecular weight surfactant-associated proteins in the lungs of infants dying with respiratory distress syndrome.

Authors:  D E deMello; D S Phelps; G Patel; J Floros; D Lagunoff
Journal:  Am J Pathol       Date:  1989-06       Impact factor: 4.307

8.  Surfactant protein A in the course of respiratory distress syndrome.

Authors:  P A Stevens; B Schadow; S Bartholain; H Segerer; M Obladen
Journal:  Eur J Pediatr       Date:  1992-08       Impact factor: 3.183

Review 9.  Techniques to evaluate surfactant activity for a personalized therapy of RDS neonates.

Authors:  Chiara Autilio
Journal:  Biomed J       Date:  2021-11-07       Impact factor: 4.910

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.